Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ivania Patry"'
Autor:
Alexis Montcuquet, Henrik Kahr Mathiesen, Tomas Kalincik, Marc Girard, Karolina Hankiewicz, Marco Onofrj, Francois Grand Maison, Raed Alroughani, Mathilde Lefort, Olivier Gout, Jeannette Lechner-Scott, Marc Debouverie, Julie Prevost, Eva Havrdova, Olivier Casez, Per Soelberg Sørensen, Pierre Duquette, Jean Pelletier, Claudio Solaro, Alessandra Lugaresi, Francesco Patti, Emmanuelle Leray, Johanna Balslev Andersen, Bassem Yamout, Céline Labeyrie, Karen Schreiber, Eric Thouvenot, Nils Koch-Henriksen, Michael Broksgaard Jensen, Elisabeth Maillart, Chantal Nifle, Stephan Bramow, Pierre Clavelou, Bruno Stankoff, Olivier Heinzlef, Finn Sellebjerg, Abir Wahab, Mark Slee, Gilles Defer, Pierre Labauge, Melinda Magyari, Steve Vucic, Guillermo Izquierdo, Helmut Butzkueven, Peter Vestergaard Rasmussen, Bertrand Bourre, Maria Trojano, Franco Granella, Corinne Pottier, Jette L. Frederiksen, Olga Skibina, Recai Turkoglu, Ivania Patry, Pierre Grammond, Bart Van Wijmeersch, Eric Berger, Aurélie Ruet, Serkan Ozakbas, Jonathan Ciron, Tünde Csépány, Jean Philippe Camdessanche, Sandra Vukusic, Nicolas Maubeuge, David Laplaud, Cavit Boz, Christine Lebrun, Claudia C. Hilt Christensen, Patrizia Sola, Vahid Shaygannejad, Romain Casey, Murat Terzi, Philippe Cabre, Jérôme De Seze, Abdullatif Al-Khedr, Dana Horakova, Pamela A. McCombe, Daniele Spitaleri, Alexandre Prat, Gilles Edan, Hélène Zéphir, Aude Marousset, Sifat Sharmin, Diana Ferraro, Sara Eichau, Rana Karabudak, Thibault Moreau
Publikováno v:
Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f97bab4b243371f958204f4a99d850
http://hdl.handle.net/1942/34842
http://hdl.handle.net/1942/34842
Autor:
Tomas Kalincik, Marc Girard, Corinne Pottier, Murat Terzi, Jean Pelletier, Oliver Gerlach, Julie Prevost, Dana Horakova, Francois Grand'Maison, Raed Alroughani, Guillermo Izquierdo, Francesco Patti, Federico Frascoli, Maria Trojano, Franco Granella, Pamela A. McCombe, Charles B Malpas, Recai Turkoglu, Aurélie Ruet, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Helmut Butzkueven, Pierre Clavelou, Tamara Castillo Trivino, Marco Onofrj, Jean Philippe Camdessanche, Pierre Labauge, Vincent Van Pesch, Pierre Grammond, Abir Wahab, Roberto Bergamaschi, Aysun Soysal, Diana Ferraro, Bertrand Bourre, Olivier Gout, Jeannette Lechner-Scott, Sara Eichau, Emmanuelle Leray, Alexis Montcuquet, Pierre Duquette, Olivier Casez, Youssef Sidhom, Patrizia Sola, Bart Van Wijmeersch, Izanne Roos, Gilles Edan, Serkan Ozakbas, David Laplaud, Sandra Vukusic, Abdullatif Al Khedr, Céline Labeyrie, Philippe Cabre, Eric Thouvenot, Céline Louapre, Romain Casey, Alessandra Lugaresi, Riadh Gouider, Alasdair Coles, Eric Berger, Ivania Patry, Gerardo Iuliano, Elisabetta Cartechini, Cavit Boz, Karolina Hankiewicz, Eva Havrdova, Eduardo Aguera-Morales, J William L Brown, Jérôme De Seze, Bruno Stankoff, Olivier Heinzlef, Gilles Defer, Alexandre Prat, Chantal Nifle, Maria José Sá, Marc Debouverie, Daniele Spitaleri, Aude Maurousset, Thibault Moreau, Christine Lebrun-Frenay, Hélène Zéphir
Publikováno v:
Multiple Sclerosis Journal
Multiple Sclerosis Journal, SAGE Publications, 2021, ⟨10.1177/1352458520981300⟩
Multiple sclerosis journal, Vol. 27, no. 12, p. 1838-1851 (2021)
Multiple Sclerosis Journal, SAGE Publications, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology
Neurology, American Academy of Neurology, 2020, 94 (15)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Publons
Web of Science
HAL
Multiple Sclerosis Journal, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology, 2020, 94 (15)
Multiple Sclerosis Journal, SAGE Publications, 2021, ⟨10.1177/1352458520981300⟩
Multiple sclerosis journal, Vol. 27, no. 12, p. 1838-1851 (2021)
Multiple Sclerosis Journal, SAGE Publications, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology
Neurology, American Academy of Neurology, 2020, 94 (15)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Publons
Web of Science
HAL
Multiple Sclerosis Journal, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology, 2020, 94 (15)
International audience; Objective: To explore the associations of patient and disease characteristics with the duration of therapeutic lag for relapses and disability progression.Background: Therapeutic lag represents the delay from initiation of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd275779a0a2c8bfba24596975ed900
https://hdl.handle.net/11380/1251074
https://hdl.handle.net/11380/1251074
Autor:
Mark Slee, Guillermo Izquierdo, Per Soelberg Soerensen, Karen Schreiber, Alexandre Prat, Francois Grand'Maison, Maria Trojano, Franco Granella, Pierre Duquette, David Laplaud, Elisabeth Maillart, Henrik Kahr Mathiesen, Bassem Yamout, Cavit Boz, Jean Pelletier, Corinne Pottier, Jette L. Frederiksen, Claudia Christina Pfleger, Tomas Kalincik, Olivier Gout, Daniele Spitaleri, Marc Girard, Marco Onofrj, Jérôme De Seze, Helmut Butzkueven, Emmanuelle Leray, Philippe Cabre, Julie Prevost, Abullatif Al-Khedr, Aude Maurousset, Eric Berger, Sifat Sharmin, Ivania Patry, Pamela A. McCombe, Patrizia Sola, Olga Skibina, Diana Ferraro, Pierre Clavelou, Francesco Patti, Finn Sellebjerg, Niels Koch-Henriksen, Alexis Montcuquet, Recai Turkoglu, Romain Casey, Bart Van Wijmeersch, Hélène Zéphir, Pierre Grammond, Dana Horakova, Davide Maimone, Serkan Ozakbas, Céline Labeyrie, Murat Terzi, Aurélie Ruet, Steve Vucic, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Bruno Stankoff, Mathilde Lefort, Katherine Buzzard, Karolina Hankiewicz, Jean-Philippe Camdessanché, Raed Alroughani, Michael Broksgaard Jensen, Pierre Labauge, Olivier Casez, Peter Vestergaard Rasmussen, Bertrand Bourre, Olivier Heinzlef, Gilles Defer, Gilles Edan, Alessandra Lugaresi, Abir Wahab, Melinda Magyari, Anneke van der Walt, Eva Havrdova, Johanna Balslev Andersen, Chantal Nifle, Stephan Bramow, Marc Debouverie, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Eric Thouvenot
Publikováno v:
CNS Drugs
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db23efcded486e57c8c7b3dd1b8db8cf
http://hdl.handle.net/11585/853457
http://hdl.handle.net/11585/853457
High effector-memory CD8+ T-cell levels correlate with high PML risk in natalizumab-treated patients
Autor:
Marie-Hélène Delfau-Larue, Jérôme Hodel, Valérie Molinier-Frenkel, Asma Beldi-Ferchiou, Abir Wahab, Alain Créange, Ivania Patry, Matthieu Duchmann
Publikováno v:
Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders, Elsevier, 2020, 46, pp.102470-. ⟨10.1016/j.msard.2020.102470⟩
Multiple Sclerosis and Related Disorders, 2020, 46, pp.102470-. ⟨10.1016/j.msard.2020.102470⟩
Multiple Sclerosis and Related Disorders, Elsevier, 2020, 46, pp.102470-. ⟨10.1016/j.msard.2020.102470⟩
Multiple Sclerosis and Related Disorders, 2020, 46, pp.102470-. ⟨10.1016/j.msard.2020.102470⟩
Background Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab (NTZ) treatment in multiple sclerosis (MS) patients. Based on the analysis of cryopreserved cells, several reports have showed that CD62L+ CD4+ T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5a2cfccdd50401d58ece58767f0122
https://hal.archives-ouvertes.fr/hal-03491499/document
https://hal.archives-ouvertes.fr/hal-03491499/document
Autor:
Asma, Beldi-Ferchiou, Abir, Wahab, Matthieu, Duchmann, Jérôme, Hodel, Ivania, Patry, Marie-Hélène, Delfau-Larue, Valérie, Molinier-Frenkel, Alain, Créange
Publikováno v:
Multiple sclerosis and related disorders. 46
Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab (NTZ) treatment in multiple sclerosis (MS) patients. Based on the analysis of cryopreserved cells, several reports have showed that CD62L+ CD4+ T-cells percentag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::097706781d0238bf0b1ce168b3d4ba33
https://pubmed.ncbi.nlm.nih.gov/32889375
https://pubmed.ncbi.nlm.nih.gov/32889375
Autor:
Xavier Moisset, Elisabeth Maillart, Julie Pique, Ofsep Investigators, Pierre Labauge, Bruno Stankoff, Eric Thouvenot, Bertrand Bourre, Fabien Rollot, Hélène Zéphir, Nathalie Derache, Gilles Edan, Sandra Vukusic, Audrey Rico-Lamy, Christine Lebrun-Frenay, David-Axel Laplaud, Eric Berger, Nicolas Maubeuge, Ayman Tourbah, Sandrine Wiertlewski, A.-M. Guennoc, Céline Labeyrie, Patrick Vermersch, Olivier Heinzlef, Mathieu Vaillant, Karolina Hankiewicz, C. Bensa, Philippe Cabre, Jérôme De Seze, Aurélie Ruet, Thibault Moreau, Romain Casey, Ivania Patry, Romain Marignier, Abdullatif Al-Khedr, Abir Wahab, Alexis Montcuquet, Chantal Nifle, Jean-Philippe Camdessanché, Guillaume Mathey, David Brassat
Publikováno v:
JAMA neurology
JAMA neurology, American Medical Association, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA Neurol
JAMA neurology, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA neurology, American Medical Association (imprimé) / 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA neurology, American Medical Association, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA Neurol
JAMA neurology, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA neurology, American Medical Association (imprimé) / 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
International audience; Importance:Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb9fe83fce128bcf85d44168fa11c4d3
https://hal.univ-lorraine.fr/hal-02302155
https://hal.univ-lorraine.fr/hal-02302155
Autor:
Patrick Vermersch, Ivania Patry, Nicolas Maubeuge, Catherine Lubetzki, Ofsep Study Groups, David-Axel Laplaud, Bruno Stankoff, Bruno Brochet, Eric Thouvenot, Céline Labeyrie, Jean-Philippe Camdessanché, Olivier Gout, Laure Michel, Chantal Nifle, Abdullatif Al Khedr, Emmanuelle Leray, Gilles Edan, Marc Debouverie, Laetitia Barbin, David Brassat, Yohann Foucher, Thibault Moreau, Romain Casey, Jean Pelletier, Christine Lebrun-Frenay, Sandra Vukusic, Laurent Magy, Olivier Heinzlef, Philippe Cabre, Caroline Papeix, Ayman Tourbah, Gilles Defer, Abir Wahab, Pierre Clavelou, Eric Berger, Jérôme De Seze, A.-M. Guennoc, Fabien Rollot, Olivier Casez, Sandrine Wiertlewski, Thomas Debroucker, Pierre Labauge, Bertrand Bourre
Publikováno v:
Neurology
Neurology, 2019, 93 (7), pp.e635-e646. ⟨10.1212/WNL.0000000000007938⟩
Neurology, American Academy of Neurology, 2019, 93 (7), pp.e635-e646. ⟨10.1212/WNL.0000000000007938⟩
Neurology, 2019, 93 (7), pp.e635-e646. ⟨10.1212/WNL.0000000000007938⟩
Neurology, American Academy of Neurology, 2019, 93 (7), pp.e635-e646. ⟨10.1212/WNL.0000000000007938⟩
ObjectiveIn this study, we compared the effectiveness of teriflunomide (TRF) and dimethyl fumarate (DMF) on both clinical and MRI outcomes in patients followed prospectively in the Observatoire Français de la Sclérose en Plaques.MethodsA total of 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa22a71c8a541129b602f45320b45d13
https://www.hal.inserm.fr/inserm-02289153
https://www.hal.inserm.fr/inserm-02289153
Autor:
N. Brieu, David Leyssene, Richard Bonnet, Florence Doucet-Populaire, C. Recule, Laurent Bret, Stéphane Bonacorsi, Nejla Aissa, M Colomb-Cotinat, Nicolas Fortineau, Valérie Ponties, A. Chapuis, Vincent Cattoir, Antoine Grillon, Racha Beyrouthy, Isabelle Podglajen, Nicolas Degand, Marie-Cécile Ploy, Véronique Dubois, Philippe Lanotte, Alain Ros, Ivania Patry, Frédéric Robin, Hubert Chardon
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2016, 61 (3), pp.1-13. ⟨10.1128/AAC.01911-16⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (3), 13 p. ⟨10.1128/AAC.01911-16⟩
Antimicrobial Agents and Chemotherapy 3 (61), 1-13. (2017)
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2016, 61 (3), pp.1-13. 〈10.1128/AAC.01911-16〉
Antimicrobial Agents and Chemotherapy, 2017, 61 (3), 13 p. ⟨10.1128/AAC.01911-16⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2016, 61 (3), pp.1-13. ⟨10.1128/AAC.01911-16⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (3), 13 p. ⟨10.1128/AAC.01911-16⟩
Antimicrobial Agents and Chemotherapy 3 (61), 1-13. (2017)
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2016, 61 (3), pp.1-13. 〈10.1128/AAC.01911-16〉
Antimicrobial Agents and Chemotherapy, 2017, 61 (3), 13 p. ⟨10.1128/AAC.01911-16⟩
The objective of this study was to perform an inventory of the extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae isolates responsible for infections in French hospitals and to assess the mechanisms associated with ESBL diffusion. A t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f75e9deb456f72ffafa6c6db14c6d2bc
https://pubmed.ncbi.nlm.nih.gov/27956424
https://pubmed.ncbi.nlm.nih.gov/27956424
Publikováno v:
Pratique Neurologique - FMC. 2:183-187
Resume Si la nevrite optique est un mode frequent de revelation d’une sclerose en plaques (SEP), les atteintes isolees d’autres nerfs crâniens sont plus rares et les atteintes multiples exceptionnelles. Nous rapportons le cas d’une patiente â
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::683b7ad457f2d1964afa2914c48f54d3
https://doi.org/10.1016/j.praneu.2011.05.004
https://doi.org/10.1016/j.praneu.2011.05.004
Autor:
Fabien Rollot, Gilles Edan, Alain Créange, Ivania Patry, A. Al Khedr, T. De Broucker, C. Dupel-Pottier, Céline Labeyrie, Olivier Gout, David Brassat, Chantal Nifle, Emmanuelle Leray, Patrick Vermersch, A.-M. Guennoc, Marc Debouverie, Catherine Lubetzki, Pierre Clavelou, David-Axel Laplaud, Olivier Casez, Yohann Foucher, Jonathan Ciron, Laurent Magy, J. de Seze, Giovanni Castelnovo, Eric Berger, Romain Casey, Olivier Heinzlef, Jean Pelletier, Ayman Tourbah, Laetitia Barbin, Sandrine Wiertlewski, J.-P. Camdessanché, de la part de la Sfsep de l’OFSEP, Bruno Brochet, Thibault Moreau, B. Stankoff, Sandra Vukusic, Gilles-Louis Defer, Christine Lebrun-Frenay, Pierre Labauge, Bertrand Bourre
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 66:S201
Introduction Le Teriflunomide (TRF) et le Dimethyl-Fumarate (DMF) sont deux traitements approuves de 1re ligne pour la forme remittente de sclerose en plaques (SEP). Cependant, a ce jour, il n’existe aucun essai randomise ni aucune etude observatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff3db61d32ad9559dc19b9487eeff59a
https://doi.org/10.1016/j.respe.2018.04.009
https://doi.org/10.1016/j.respe.2018.04.009